FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Johnson & Johnson (NYSE: JNJ) Delayed: 231.29 +2.90 (1.27%)
Previous Close $228.39    52 Week High $126.07 
Open $228.95    52 Week Low $94.28 
Day High $231.45    P/E 48.09 
Day Low $227.50    EPS $4.81 
Volume 8,398,592